Inhibrx Biosciences (INBX) Reiterated at Buy by Stifel After Ozekibart Data Presentation
Tweet Send to a Friend
Stifel analyst Dara Azar reiterated a Buy rating and $325.00 price target on Inhibrx Biosciences (NASDAQ: INBX).The analyst commented, "Over ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
